Bioxcel therapeutics to announce topline results from serenity at-home pivotal phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia on august 27, 2025

New haven, conn., aug. 26, 2025 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will host an investor call and live webcast at 8 a.m.
BTAI Ratings Summary
BTAI Quant Ranking